Annual Report 10-11 - Elder Pharmaceuticals Ltd.

Recommendations

Info

A niche isan intellectual space,which needs to be constantlyenriched through a combination ofglobal acquisitions and alliances.Our global alliances and acquisitions have onepresence and expand our international footprintby providing access to foreign markets andINVESTMENTSCumulative investment around`` 40 crore in Elder10
28 th Annual Report2010 - 11Company OverviewBoard and Management ReportsFinancial StatementsOther strategic alliance includes:Its fully-owned subsidiaries comprise:Brunel Healthcare Manufacturing Ltd. (Brunel)Primarily catering to private labels businessSpecializes in the development, manufacture, distribution and packaging ofBiocare Ltd.Involved in prescription drugs business; communication with customers/potential clients is conducted through the Company’s online portal and Synergetic operations better terms and volume discounts with existing vendors, stability andNeutrahealth’s products are sold over the counter and the company is alsowill provide raw materials for certain brands of Elder; on the other hand,Elder Raising stake in Elder Biomeda (Bulgaria)`Future operations of Elder Biomeda `Also, an investment is being planned to build and buy dossiers of off-patentIt will act as a large manufacturing base, ensuring ease of supply to variousCommencement of in-plant manufacturing will not only generate highformulations and bulk drugs toIslands, Colombia, Ghana,Maldives, Mauritius, Mexico,Nigeria, the Philippines,export infrastructure can beproducts, boosting sales and11
Page 2 and 3: COMPANY OVERVIEWNiche is the result
Page 4 and 5: Niche is theresult of innovat vespi
Page 6: Chairman’s MessageDear Shareholde
Page 14 and 15: Creatinga niche throughowned market
Page 16 and 17: Niche expertiseDEVELOPINGINTERNATIO
Page 18 and 19: Brands representour distinctiveasse
Page 20 and 21: Nutraceuticalscombination specializ
Page 23 and 24: 28 th Annual Report2010 - 11Company
Page 27 and 28: Annual Report2010 - 11Company Overv
Page 33 and 34: Directors’ Report28 th Annual Rep
Page 37 and 38: Annexure - I28 th Annual Report2010
Page 41 and 42: Report on CorporateGovernance28 th
Page 53 and 54: Auditors’ Report28 th Annual Repo
Page 57 and 58: for the year ended 31st March 20112
Page 59 and 60: Cash Flow Statement28 th Annual Rep
Page 61 and 62:
Schedules to Balance Sheetas at 31s
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
year ended 31st March 201128 th Ann
Page 69 and 70:
28 th Annual Report2010 - 11Schedul
Page 71:
28 th Annual Report2010 - 11Company
Page 74 and 75:
8. Purchases of Finished Goods :` P
Page 76 and 77:
ParticularsGratutity31st March2011
Page 78 and 79:
BALANCE SHEET ABSTRACT AND COMPANY'
Page 80 and 81:
Pharmaceuticals Ltd.Consolidated Ba
Page 82 and 83:
Pharmaceuticals Ltd.Consolidated Ca
Page 84 and 85:
Pharmaceuticals Ltd.Consolidated Sc
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Pharmaceuticals Ltd.year ended 31st
Page 92 and 93:
Pharmaceuticals Ltd.year ended 31st
Page 94 and 95:
Pharmaceuticals Ltd.Exchange differ
Page 96 and 97:
Pharmaceuticals Ltd.As At31st March
Page 98 and 99:
Pharmaceuticals Ltd.CONSOLIDATED BA
Page 100 and 101:
International FZCO, Dubai, U.A.E.Fi
Page 102 and 103:
International FZCO, Dubai, U.A.E.Fi
Page 104 and 105:
Somerta Holdings Co. Limited (Cypru
Page 106 and 107:
Pharmaceuticals Ltd.NoticeNotice is
Page 108 and 109:
Pharmaceuticals Ltd.including terms
Page 110 and 111:
Pharmaceuticals Ltd.9. The dividend
Page 112 and 113:
Pharmaceuticals Ltd.Notes..........
Page 114 and 115:
Pharmaceuticals Ltd.Notes..........
Page 116:
Pharmaceuticals Ltd.ELECTRONIC CLEA
Page 120:
Elder HouseC-9, Dalia Industrial Es
show all

Annual Report 10-11 - Elder Pharmaceuticals Ltd.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?